Abcellera Biologics Inc
NASDAQ:ABCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
China Leon Inspection Holding Ltd
HKEX:1586
|
CN |
|
Vantage Towers AG
XETRA:VTWR
|
DE |
Abcellera Biologics Inc
Stock-Based Compensation
Abcellera Biologics Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Stock-Based Compensation
$55.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abcellera Biologics Inc
Glance View
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
See Also
What is Abcellera Biologics Inc's Stock-Based Compensation?
Stock-Based Compensation
55.8m
USD
Based on the financial report for Dec 31, 2025, Abcellera Biologics Inc's Stock-Based Compensation amounts to 55.8m USD.
What is Abcellera Biologics Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
46%
Over the last year, the Stock-Based Compensation growth was -17%. The average annual Stock-Based Compensation growth rates for Abcellera Biologics Inc have been 4% over the past three years , 46% over the past five years .
